Peter Hamer

531 total citations
22 papers, 457 citations indexed

About

Peter Hamer is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Peter Hamer has authored 22 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Peter Hamer's work include Protease and Inhibitor Mechanisms (8 papers), Peptidase Inhibition and Analysis (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Peter Hamer is often cited by papers focused on Protease and Inhibitor Mechanisms (8 papers), Peptidase Inhibition and Analysis (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Peter Hamer collaborates with scholars based in United States, Switzerland and Denmark. Peter Hamer's co-authors include Walter P. Carney, Richard A. Laursen, Anthony J. Capobianco, Thomas D. Gilmore, George Mosialos, Allan Lipton, Suhail M. Ali, Dean B. Evans, Laurence M. Demers and Hilary A. Chaudri‐Ross and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Molecular and Cellular Biology.

In The Last Decade

Peter Hamer

21 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Hamer United States 12 226 208 189 77 73 22 457
MC Rio France 9 213 0.9× 206 1.0× 266 1.4× 88 1.1× 109 1.5× 13 514
S. G. Shering Ireland 8 200 0.9× 140 0.7× 175 0.9× 37 0.5× 50 0.7× 11 484
David Browell United Kingdom 13 277 1.2× 129 0.6× 286 1.5× 76 1.0× 47 0.6× 26 608
Crispinita D. Arroyo United States 12 375 1.7× 220 1.1× 224 1.2× 81 1.1× 108 1.5× 12 663
Renata Kusińska Poland 14 248 1.1× 166 0.8× 256 1.4× 24 0.3× 118 1.6× 25 550
Melinda S. Gordon United States 10 195 0.9× 251 1.2× 394 2.1× 155 2.0× 29 0.4× 25 683
Naila Chughtai Canada 9 343 1.5× 106 0.5× 326 1.7× 106 1.4× 68 0.9× 9 559
Peter Čamaj Germany 16 355 1.6× 279 1.3× 507 2.7× 81 1.1× 76 1.0× 22 788
K Imai Japan 12 170 0.8× 70 0.3× 265 1.4× 129 1.7× 24 0.3× 14 423
Ken Ryder United Kingdom 8 383 1.7× 368 1.8× 155 0.8× 48 0.6× 72 1.0× 11 668

Countries citing papers authored by Peter Hamer

Since Specialization
Citations

This map shows the geographic impact of Peter Hamer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hamer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hamer more than expected).

Fields of papers citing papers by Peter Hamer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hamer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hamer. The network helps show where Peter Hamer may publish in the future.

Co-authorship network of co-authors of Peter Hamer

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hamer. A scholar is included among the top collaborators of Peter Hamer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hamer. Peter Hamer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oh, William, Roberto Vargas, Susanna Jacobus, et al.. (2010). Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients. Cancer. 117(3). 517–525. 31 indexed citations
2.
Hamer, Peter, et al.. (2010). Abstract 826: Expression levels of circulating soluble-EphA2 receptor in cancer patients. Cancer Research. 70(8_Supplement). 826–826. 1 indexed citations
3.
Hamer, Peter, Sheryl Brown‐Shimer, & Walter P. Carney. (2009). Abstract #244: A Standardized CAIX immunohistochemistry test for use in formalin-fixed, paraffin-embedded (FF-PE) sections. Cancer Research. 69. 244–244. 1 indexed citations
4.
Terpos, Evangelos, Meletios Α. Dimopoulos, Vikas Shrivastava, et al.. (2009). High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research. 34(3). 399–402. 16 indexed citations
5.
Lipton, Allan, Kim Leitzel, Hilary A. Chaudri‐Ross, et al.. (2008). Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer. Journal of Clinical Oncology. 26(16). 2653–2658. 39 indexed citations
6.
Lipton, Allan, Suhail M. Ali, Kim Leitzel, et al.. (2007). Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 109(10). 1933–1939. 40 indexed citations
7.
Oh, William, Kim Leitzel, Philip W. Kantoff, et al.. (2007). Elevated plasma TIMP-1 levels predict reduced survival in metastatic hormone-refractory prostate cancer patients. Journal of Clinical Oncology. 25(18_suppl). 5143–5143. 1 indexed citations
8.
Leitzel, Kim, Suhail M. Ali, Laurence M. Demers, et al.. (2006). Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer. Cancer. 107(10). 2337–2345. 33 indexed citations
9.
Leitzel, Kim, Suhail M. Ali, Hamid Al‐Mondhiry, et al.. (2006). Elevated serum ras level predicts decreased survival in patients with hematologic malignancies. Journal of Clinical Oncology. 24(18_suppl). 6562–6562. 1 indexed citations
10.
Lipton, Allan, Kim Leitzel, Suhail M. Ali, et al.. (2005). Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 104(2). 257–263. 81 indexed citations
11.
Leitzel, Kim, Suhail M. Ali, Laurence M. Demers, et al.. (2005). Serum EGFR/HER-2 combination predicts poor survival in metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 9613–9613. 2 indexed citations
12.
Ali, Suhail M., Kim Leitzel, Walter P. Carney, et al.. (2004). Pretreatment serum uPA and survival in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 4247–4247. 2 indexed citations
13.
Clarke, Lauren, Kim Leitzel, Siraj M. Ali, et al.. (2001). Serum urokinase-type plasminogen activator (UPA) as a prognostic factor in metastatic breast cancer. European Journal of Cancer. 37. S117–S117. 1 indexed citations
14.
Hamer, Peter, et al.. (1991). Production and Characterization of Monoclonal Antibodies to Ha- ras and N- ras p21. Hybridoma. 10(4). 467–480. 3 indexed citations
15.
Mosialos, George, Peter Hamer, Anthony J. Capobianco, Richard A. Laursen, & Thomas D. Gilmore. (1991). A Protein Kinase-Α Recognition Sequence Is Structurally Linked to Transformation by p59 v-rel and Cytoplasmic Retention of ρ68 c-rel. Molecular and Cellular Biology. 11(12). 5867–5877. 26 indexed citations
16.
Garlick, David S., Saraswati Sukumar, Mariano Barbacid, et al.. (1991). Generation of Monoclonal Antibodies Specific For ras p21 Glu-12 Oncoproteins: Detection in Carcinogen-Induced Mammary Carcinomas. Hybridoma. 10(1). 95–102. 4 indexed citations
17.
Mosialos, George, Peter Hamer, Anthony J. Capobianco, Richard A. Laursen, & Thomas D. Gilmore. (1991). A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel.. Molecular and Cellular Biology. 11(12). 5867–5877. 97 indexed citations
18.
Hamer, Peter, et al.. (1990). Production and Characterization of Anti- RAS p21 Monoclonal Antibodies. Hybridoma. 9(6). 573–587. 18 indexed citations
19.
Carney, Walter P., Peter Hamer, Channing J. Der, et al.. (1986). Monoclonal antibody specific for an activated RAS protein.. Proceedings of the National Academy of Sciences. 83(19). 7485–7489. 24 indexed citations
20.
Robinson, Derrick R., et al.. (1981). Mechanism of stimulation of prostaglandin synthesis by a factor from rheumatoid synovial tissue.. Proceedings of the National Academy of Sciences. 78(8). 5160–5164. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MC Rio Breakdown of academic impact, for papers by S. G. Shering Breakdown of academic impact, for papers by David Browell Breakdown of academic impact, for papers by Crispinita D. Arroyo Breakdown of academic impact, for papers by Renata Kusińska Breakdown of academic impact, for papers by Melinda S. Gordon Breakdown of academic impact, for papers by Naila Chughtai Breakdown of academic impact, for papers by Peter Čamaj Breakdown of academic impact, for papers by K Imai Breakdown of academic impact, for papers by Ken Ryder
Rankless by CCL
2026